Fig. 1
From: Affinity fine-tuning anti-CAIX CAR-T cells mitigate on-target off-tumor side effects
Quantification of CAIX on patient ccRCC samples, healthy bile duct, and cell lines. (A) IHC staining of CAIX on ccRCC and bile duct samples. (B) CAIX positivity quantified by IHC on ccRCC patient samples from different stages, Stage I (red), Stage II (orange), Stage III (blue) and Stage IV (green). (C) High resolution representative images of CAIX on ccRCC (pink), bile duct (orange), skrc-59 CAIX+ cell line (red), sgCAIX skrc-59 cell line (green) and MMNK-1 cell line (blue). (D) Bar plot of CAIX expression quantified by dSTORM presented by number of clusters on ccRCC (pink), bile duct (orange), skrc-59 CAIX+ cell line (red), sgCAIX skrc-59 cell line (green) and MMNK-1 cell line (blue). (E) Bar plot of CAIX expression quantified by flow cytometry on skrc-59 CAIX+ cell line (red), sgCAIX skrc-59 cell line (green) and MMNK-1 cell line (blue) with mean values of 195,176, 523, 1189 accordingly. (F) Bar plot of CAIX expression quantified by flow cytometry on ccRCC patient samples from primary and lung metastatic lesions, primary (red, n = 10), lung metastatic (orange, n = 5), with mean values of 10,396, 19,292 accordingly. All data with error bars are presented as mean ± SD. P values are defined by unpaired two-tailed t-tests (*p < 0.05; **p < 0.01; ***p < 0.001; and ****p < 0.0001)